1 Biostem Technologies, Inc. Receivables Turnover Ratio (BSEM), from the second quarter 2026 to the second quarter current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
BioStem Technologies, Inc.  (Nasdaq: BSEM)
 

Biostem Technologies Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter

Quarterly Results, Trends, Rankings, Statistics


Biostem Technologies, Inc.'s ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 4.57, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Biostem Technologies in Jun 30 2026 quarter, has decreased to 80 days, compared to 82 days, in the Jun 30 2025 quarter.

If we take a look into Healthcare sector BioStem Technologies, Inc. achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Biostem Technologies, Inc. Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BSEM Receivables Turnover Ratio (Jun 30 2026)
II. Quarter		 (Jun 30 2025)
II. Quarter


Y / Y Receivable Change - - - - -
Y / Y Revenue Change - - - - -
Receivable Turnover Ratio (TTM) 4.57 4.44 - - -
BSEM's Total Ranking # # # # #
Accounts Receivable average collection period days 80 82 - - -
Seq. Receivable Change -32.94 % - - - -
Seq. Revenue Change -27.95 % - - - -


Receivable Turnover Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #

Receivable Turnover Ratio Statistics
High Average Low
0 0 0
 





BSEM Company Profile • Back to BSEM Efficiency Comparisons • Compare BSEM Receivables Turnover Ratio to its Competitors

Financial Statements
Biostem Technologies's Accounts Receivable $ 7 Millions Visit BSEM's Balance sheet
Biostem Technologies's Sales TTM $ 19 Millions Visit BSEM's Income Statement
Sources of BSEM's Revenues Visit BSEM's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
BSEM's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
BSEM's Growth Rates BSEM's Roa BSEM's Inventory Turnover Ratio BSEM's Dividend Comparisons
BSEM's Profitability Ratios BSEM's Roi BSEM's Asset Turnover Ratio BSEM's Dividend Growth
BSEM's Valuation Ratios BSEM's Roe BSEM's Financial Strength Ratios BSEM's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
Exelixis Inc   7.81 $ 2,435.920  Millions$ 311.950  Millions
Castle Biosciences Inc   7.79 $ 357.278  Millions$ 45.867  Millions
Trisalus Life Sciences Inc   7.78 $ 45.179  Millions$ 5.808  Millions
Idexx Laboratories Inc  7.75 $ 4,553.792  Millions$ 587.472  Millions
Vycor Medical Inc   7.68 $ 1.807  Millions$ 0.235  Millions
Aurinia Pharmaceuticals Inc   7.67 $ 311.507  Millions$ 40.624  Millions
Beta Bionics Inc   7.65 $ 119.513  Millions$ 15.615  Millions
Lemaitre Vascular Inc   7.65 $ 262.923  Millions$ 34.370  Millions
Novocure Limited  7.62 $ 699.193  Millions$ 91.768  Millions
Natera Inc   7.61 $ 2,707.077  Millions$ 355.618  Millions
Co diagnostics Inc   7.58 $ 0.721  Millions$ 0.095  Millions
Quest Diagnostics Inc  7.56 $ 11,560.000  Millions$ 1,529.250  Millions
Fortress Biotech Inc   7.55 $ 69.983  Millions$ 9.266  Millions
Protalix Biotherapeutics inc   7.55 $ 80.619  Millions$ 10.677  Millions
Pmgc Holdings Inc   7.55 $ 2.579  Millions$ 0.342  Millions
Solventum Corporation  7.52 $ 8,310.000  Millions$ 1,105.500  Millions
Iridex Corp  7.49 $ 51.044  Millions$ 6.816  Millions
Merit Medical Systems Inc  7.48 $ 1,579.403  Millions$ 211.171  Millions
Intuitive Surgical Inc   7.46 $ 11,296.300  Millions$ 1,513.950  Millions
Edap Tms Sa  7.44 $ 109.370  Millions$ 14.699  Millions
Transmedics Group Inc   7.43 $ 668.468  Millions$ 89.962  Millions
Acadia Healthcare Company Inc   7.43 $ 3,367.673  Millions$ 453.486  Millions
Seres Therapeutics Inc   7.42 $ 1.883  Millions$ 0.254  Millions
Blue Water Vaccines Inc  7.41 $ 0.646  Millions$ 0.087  Millions
Renovorx Inc   7.40 $ 1.976  Millions$ 0.267  Millions
Maravai Lifesciences Holdings Inc   7.39 $ 207.886  Millions$ 28.147  Millions
Nurix Therapeutics Inc   7.35 $ 36.766  Millions$ 5.000  Millions
Cerus Corporation  7.35 $ 221.224  Millions$ 30.111  Millions
Anteris Technologies Global Corp   7.34 $ 2.242  Millions$ 0.305  Millions
Palatin Technologies Inc   7.34 $ 13.185  Millions$ 1.797  Millions

Date modified: 2026-10-24T05:30:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.